PCSK9: A new participant in lipophagy in regulating atherosclerosis?

被引：10
作者：
Xiao, Jun [1 ]
Deng, Yi-Min [1 ]
Liu, Xiang-Rui [1 ]
Cao, Jian-Ping [2 ]
Zhou, Min [1 ]
Tang, Ya-Ling [1 ]
Xiong, Wen-Hao [1 ]
Jiang, Zhi-Sheng [1 ]
Tang, Zhi-Han [1 ]
Liu, Lu-Shan [1 ]
机构：
[1] Univ South China, Hunan Int Sci & Technol Cooperat Base Arterioscle, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China
[2] Hunan Environm Biol Vocat & Tech Coll, Hengyang 421001, Hunan, Peoples R China
来源：
CLINICA CHIMICA ACTA | 2019年 / 495卷
基金：
中国国家自然科学基金;
关键词：
Proprotein convertase subtilisin kexin 9; Lipophagy; Lipid metabolism; Low density lipoprotein receptor; Atherosclerosis; SUBTILISIN/KEXIN TYPE 9; LIPID DROPLETS; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; APOLIPOPROTEIN-B; RAB7; EFFECTOR; LIVER-DISEASE; AUTOPHAGY; PROTEIN; DEGRADATION;
D O I：
10.1016/j.cca.2019.05.005
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis.
引用
收藏
页码：358 / 364
页数：7
相关论文
共 50 条
[31]   PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation [J].
Luquero, Aureli ;
Badimon, Lina ;
Borrell-Pages, Maria .
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
[32]   PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis [J].
Momtazi-Borojeni, Amir Abbas ;
Jaafari, Mahmoud Reza ;
Afshar, Mohammad ;
Banach, Maciej ;
Sahebkar, Amirhossein .
ARCHIVES OF MEDICAL SCIENCE, 2021, 17 (05) :1365-1377
[33]   Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis [J].
Wang, Yanan ;
Fang, Dan ;
Yang, Qinzhi ;
You, Jingcan ;
Wang, Liqun ;
Wu, Jianbo ;
Zeng, Min ;
Luo, Mao .
FRONTIERS IN IMMUNOLOGY, 2023, 14
[34]   PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography [J].
Panahi, Yunes ;
Ghahrodi, Mohsen Sadeghi ;
Jamshir, Mohsen ;
Safarpour, Mohammad Amin ;
Bianconi, Vanessa ;
Pirro, Matteo ;
Farahani, Maryam Moshkani ;
Sahebkar, Amirhossein .
CLINICAL BIOCHEMISTRY, 2019, 74 :12-18
[35]   PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction [J].
Sun, Hua ;
Krauss, Ronald M. ;
Chang, Jeffrey T. ;
Teng, Ba-Bie .
JOURNAL OF LIPID RESEARCH, 2018, 59 (02) :207-223
[36]   PCSK9 as a therapeutic target for cardiovascular disease [J].
Zhang, Pei-Ying .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (03) :810-814
[37]   Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis [J].
Li, Sha ;
Guo, Yuan-Lin ;
Xu, Rui-Xia ;
Zhang, Yan ;
Zhu, Cheng-Gang ;
Sun, Jing ;
Qing, Ping ;
Wu, Na-Qiong ;
Li, Jian-Jun .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 174 (03) :863-864
[38]   Heart to heart with PCSK9 [J].
Chemello, Kevin ;
Jaafar, Ali K. ;
Lambert, Gilles .
EUROPEAN HEART JOURNAL, 2021, 42 (32) :3091-3093
[39]   Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis [J].
Lu, Xinjie .
CURRENT DRUG TARGETS, 2019, 20 (10) :1029-1040
[40]   PCSK9: a convertase that coordinates LDL catabolism [J].
Horton, Jay D. ;
Cohen, Jonathan C. ;
Hobbs, Helen H. .
JOURNAL OF LIPID RESEARCH, 2009, 50 :S172-S177
12345